Trials / Recruiting
RecruitingNCT04581512
Study to Evaluate the Safety and Tolerability of EP0042
A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Ellipses Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EP0042 | EP0042 Oral 20 mg 50 mg capsules |
| DRUG | Venetoclax | Venetoclax |
| DRUG | Azacitidine (AZA) | Azacitidine |
Timeline
- Start date
- 2020-11-02
- Primary completion
- 2025-10-01
- Completion
- 2026-12-01
- First posted
- 2020-10-09
- Last updated
- 2025-10-14
Locations
6 sites across 3 countries: Australia, Netherlands, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04581512. Inclusion in this directory is not an endorsement.